TIMP1 and cancer: From all markers characterizing the CTCs population in our cohort of patients we selected TIMP1, because of its relevance in cancer progression in other cancer subtypes [13,14,15] including triple negative breast cancer where our group found this marker previously [16], for a further in vitro and in vivo characterization.